IMS：全球仿制药市场专用课件.pptVIP

* * * * Claire Machin March 2011 Patent Cliff Info Value of patent cliff for products with patent expiries (Q3+4 only for 2011) 2011-2015 = $160Bn (Market Seg countries only) Top 10 products losing protection (Q3+4 only for 2011) 2011-2015 and their market share of $160Bn from above LIPITOR 7% SERETIDE 5% PLAVIX 5% NEXIUM 4% SEROQUEL 4% ABILIFY 4% YPREXA 3% SINGULAIR 3% CYMBALTA 3% ACTOS 2% USA Negative OB volume growth Forecasted at -1.5% in 2011 but will recover to produce a growth of 1.5% in 2013 EU5 Improving access to drugs in France A new national plan for rare diseases (Plan National Maladies Rares, PNMR), covering the years 2011-2014, has been presented by the government. Total funding of €180 million has been allocated to the plan, which aims to improve diagnosis and treatment, promote research into rare diseases and encourage greater European/international collaboration (by sharing expertise etc). Included in the key measures are two initiatives to improve access to drugs. The government will simplify the procedure for obtaining reimbursement approval for drugs used outside of their authorised indications, or non-reimbursable drugs, including in cases where there are little available data on the drugs risk-benefit profile (the key deciding factor in authorising such applications). Retail pharmacies will be authorised to dispense experimental drugs to patients suffering from rare diseases who are participating in clinical trials. Currently, such drugs can only be dispensed by hospitals. Value based pricing in UK The government has launched a consultation on proposals to introduce value-based pricing for branded drugs once the current Pharmaceutical Price Regulation Scheme (PPRS) expires at the end of 2013. The new pricing system is intended to improve drug access and ensure the best use of National Health Service (NHS) resources, while stimulating innovation and the development of medicines in areas of greatest unmet need. The new value